PROM1 and glioblastoma: For example, CD133+ cells in GBM, identified by flow cytometry, have been considered tumor-initiating cells and have been demonstrated to be responsible for the proliferation of tumor cells, as well as resistance to radiation therapy based on immune-deficient NOD/SCID mouse xenograft models (77).